Head-to-head · WeighScore
NuuVim vs TrueMe
The verdict
NuuVim takes it — 71.1/100 to 67.4/100.
NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NuuVim | TrueMe |
|---|---|---|
| WeighScore | 71.1/100 | 67.4/100 |
| Grade | C | C |
| Scorecard rank | #101 | #171 |
| Semaglutide | $79/mo (all doses, compounded) | $159/mo (compounded) |
| Tirzepatide | $133/mo (all doses, compounded) | $189/mo (compounded) |
| Coverage | Coverage not published | 6 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #101 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- No founder, CEO, medical director, or pharmacist-in-charge named
- Refund and cancellation policy not surfaced on the site
- Compounded medications are not FDA-approved
- Doesn't disclose which pharmacy fills which drug or form
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Graded #171 · C
Strengths
- One price covers consultation, medication, shipping, supplies and provider support, and the site states there are no separate membership fees
- Same price at every dose, so the cost does not climb as a provider titrates the dose upward
- Full pricing is published up front — no intake form is required before you can see what you will pay
- Carries a genuine LegitScript-issued seal (ID 50205625) that resolves on LegitScript's own asset host
- Names its telehealth platform (Telegra) and physician network (Strive), and the returns address names CarePoint Infusion Pharmacy in Stafford, Texas
Where it loses points
- Serves only six states (AZ, CO, MO, PA, TX, WI), far narrower coverage than most national GLP-1 telehealth
- Prices marketed per month are charged every 4 weeks at checkout — 13 charges a year, not 12
- You pay before completing the medical intake, and approval is not guaranteed at the moment you are charged
- The 3-month rates ($119 and $139/mo) are a single upfront charge of $357 or $417, not a lower monthly plan
- A Featured In strip shows CNN, Fox News, Forbes, New York Times and NPR logos with no linked coverage
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.